Upcoming Dividend • Jun 02
Upcoming dividend of HK$0.30 per share Eligible shareholders must have bought the stock before 09 June 2026. Payment date: 13 July 2026. Payout ratio is a comfortable 28% and this is well supported by cash flows. Trailing yield: 1.7%. Lower than top quartile of Hong Kong dividend payers (6.9%). Lower than average of industry peers (3.4%). New Risk • May 28
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Hong Kong stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Valuation Update With 7 Day Price Move • May 26
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to HK$13.60, the stock trades at a forward P/E ratio of 8x. Average forward P/E is 7x in the Chemicals industry in Hong Kong. Total returns to shareholders of 117% over the past three years. Reported Earnings • Apr 28
Full year 2025 earnings: EPS and revenues miss analyst expectations Full year 2025 results: EPS: CN¥0.98 (up from CN¥0.46 in FY 2024). Revenue: CN¥14.4b (up 1.2% from FY 2024). Net income: CN¥1.64b (up 102% from FY 2024). Profit margin: 11% (up from 5.7% in FY 2024). The increase in margin was primarily driven by lower expenses. Revenue missed analyst estimates by 6.4%. Earnings per share (EPS) also missed analyst estimates by 8.2%. Revenue is forecast to grow 8.1% p.a. on average during the next 3 years, compared to a 5.5% growth forecast for the Chemicals industry in Hong Kong. Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has increased by 16% per year, which means it is well ahead of earnings. New Risk • Mar 30
New minor risk - Dividend sustainability The company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 2.7% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. This is currently the only risk that has been identified for the company. Declared Dividend • Mar 27
Dividend of HK$0.30 announced Shareholders will receive a dividend of HK$0.30. Ex-date: 9th June 2026 Payment date: 13th July 2026 Dividend yield will be 2.7%, which is lower than the industry average of 8.1%. Payout Ratios Payout ratio: 12%. Cash payout ratio: 12%. Announcement • Mar 26
Dongyue Group Limited announces Annual dividend, payable on July 13, 2026 Dongyue Group Limited announced Annual dividend of HKD 0.3000 per share payable on July 13, 2026, ex-date on June 09, 2026 and record date on June 10, 2026. Reported Earnings • Mar 26
Full year 2025 earnings: EPS and revenues miss analyst expectations Full year 2025 results: EPS: CN¥0.98 (up from CN¥0.46 in FY 2024). Revenue: CN¥14.4b (up 1.2% from FY 2024). Net income: CN¥1.64b (up 102% from FY 2024). Profit margin: 11% (up from 5.7% in FY 2024). The increase in margin was primarily driven by lower expenses. Revenue missed analyst estimates by 6.2%. Earnings per share (EPS) also missed analyst estimates by 8.0%. Revenue is forecast to grow 11% p.a. on average during the next 2 years, compared to a 7.3% growth forecast for the Chemicals industry in Hong Kong. Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has increased by 11% per year, which means it is well ahead of earnings. Announcement • Mar 26
Dongyue Group Limited, Annual General Meeting, Jun 04, 2026 Dongyue Group Limited, Annual General Meeting, Jun 04, 2026. Announcement • Mar 05
Dongyue Group Limited to Report Fiscal Year 2025 Results on Mar 25, 2026 Dongyue Group Limited announced that they will report fiscal year 2025 results on Mar 25, 2026 Announcement • Jan 02
Dongyue Group Limited Announces Nomination Committee Appointments, Effective 31 December 2025 The board of directors of Dongyue Group Limited announced that Ms. Chung Tak Lai (Ms. Chung), an executive Director, and Mr. Ma Zhizhong (Mr. Ma), an independent non-executive Director, have been appointed as members of the nomination committee of the Company with effect from 31 December 2025. Following the appointment of Ms. Chung and Mr. Ma, the Nomination Committee has one Director of a different gender, and still comprises a majority of independent non-executive Directors. The above change in composition of the Nomination Committee is implemented in response to the amended Corporate Governance Code as set forth in Appendix C1 to the Rules Governing the Listing of Securities of The Stock Exchange of Hong Kong Limited (the ``Stock Exchange'') which is currently in effect. Valuation Update With 7 Day Price Move • Oct 16
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to HK$10.60, the stock trades at a forward P/E ratio of 8x. Average forward P/E is 9x in the Chemicals industry in Hong Kong. Total returns to shareholders of 47% over the past three years. Price Target Changed • Aug 28
Price target increased by 11% to HK$15.36 Up from HK$13.87, the current price target is an average from 5 analysts. New target price is 21% above last closing price of HK$12.73. Stock is up 128% over the past year. The company is forecast to post earnings per share of CN¥1.10 for next year compared to CN¥0.46 last year. Reported Earnings • Aug 28
First half 2025 earnings released: EPS: CN¥0.47 (vs CN¥0.17 in 1H 2024) First half 2025 results: EPS: CN¥0.47 (up from CN¥0.17 in 1H 2024). Revenue: CN¥7.46b (up 2.8% from 1H 2024). Net income: CN¥779.2m (up 153% from 1H 2024). Profit margin: 10% (up from 4.2% in 1H 2024). The increase in margin was primarily driven by lower expenses. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 6.2% growth forecast for the Chemicals industry in Hong Kong. Over the last 3 years on average, earnings per share has fallen by 47% per year but the company’s share price has increased by 14% per year, which means it is well ahead of earnings. Announcement • Jul 25
Dongyue Group Limited to Report First Half, 2025 Results on Aug 26, 2025 Dongyue Group Limited announced that they will report first half, 2025 results on Aug 26, 2025 Announcement • Jun 05
Dongyue Group Limited Approves Final Dividend for the Year Ended 31 December 2024 Dongyue Group Limited at the Annual General Meeting held on 5 June 2025, approved declared a final dividend of HKD 0.10 per Share for the year ended 31 December 2024. Upcoming Dividend • Jun 03
Upcoming dividend of HK$0.10 per share Eligible shareholders must have bought the stock before 10 June 2025. Payment date: 10 July 2025. Payout ratio is a comfortable 20% and this is well supported by cash flows. Trailing yield: 1.1%. Lower than top quartile of Hong Kong dividend payers (7.7%). Lower than average of industry peers (3.7%). Valuation Update With 7 Day Price Move • Apr 07
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to HK$7.70, the stock trades at a forward P/E ratio of 7x. Average forward P/E is 8x in the Chemicals industry in Hong Kong. Total loss to shareholders of 4.4% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at HK$8.32 per share. Declared Dividend • Mar 30
Dividend of HK$0.10 announced Shareholders will receive a dividend of HK$0.10. Ex-date: 10th June 2025 Payment date: 10th July 2025 Dividend yield will be 1.1%, which is lower than the industry average of 8.1%. Announcement • Mar 28
Dongyue Group Limited announces Annual dividend, payable on July 10, 2025 Dongyue Group Limited announced Annual dividend of HKD 0.1000 per share payable on July 10, 2025, ex-date on June 10, 2025 and record date on June 11, 2025. Reported Earnings • Mar 28
Full year 2024 earnings: EPS and revenues miss analyst expectations Full year 2024 results: EPS: CN¥0.46 (up from CN¥0.32 in FY 2023). Revenue: CN¥14.2b (down 2.2% from FY 2023). Net income: CN¥810.8m (up 15% from FY 2023). Profit margin: 5.7% (up from 4.9% in FY 2023). The increase in margin was driven by lower expenses. Revenue missed analyst estimates by 10%. Earnings per share (EPS) also missed analyst estimates by 2.5%. Revenue is forecast to grow 13% p.a. on average during the next 2 years, compared to a 6.2% growth forecast for the Chemicals industry in Hong Kong. Over the last 3 years on average, earnings per share has fallen by 44% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings. Announcement • Mar 28
Dongyue Group Limited, Annual General Meeting, Jun 05, 2025 Dongyue Group Limited, Annual General Meeting, Jun 05, 2025. Buy Or Sell Opportunity • Mar 19
Now 22% overvalued after recent price rise Over the last 90 days, the stock has risen 27% to HK$9.70. The fair value is estimated to be HK$7.98, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 17%. Revenue is forecast to grow by 23% in 2 years. Earnings are forecast to grow by 173% in the next 2 years. Buy Or Sell Opportunity • Feb 26
Now 26% overvalued after recent price rise Over the last 90 days, the stock has risen 28% to HK$8.73. The fair value is estimated to be HK$6.94, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 17%. Revenue is forecast to grow by 22% in 2 years. Earnings are forecast to grow by 155% in the next 2 years. Announcement • Feb 24
Dongyue Group Limited to Report Fiscal Year 2024 Results on Mar 27, 2025 Dongyue Group Limited announced that they will report fiscal year 2024 results on Mar 27, 2025 Buy Or Sell Opportunity • Dec 17
Now 21% overvalued after recent price rise Over the last 90 days, the stock has risen 30% to HK$7.17. The fair value is estimated to be HK$5.91, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 17%. Revenue is forecast to grow by 26% in 2 years. Earnings are forecast to grow by 156% in the next 2 years. Major Estimate Revision • Oct 24
Consensus EPS estimates fall by 14% The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from CN¥17.6b to CN¥16.6b. EPS estimate also fell from CN¥0.748 per share to CN¥0.644 per share. Net income forecast to grow 103% next year vs 49% growth forecast for Chemicals industry in Hong Kong. Consensus price target broadly unchanged at HK$11.89. Share price fell 4.7% to HK$6.33 over the past week. Reported Earnings • Sep 29
First half 2024 earnings released: EPS: CN¥0.17 (vs CN¥0.13 in 1H 2023) First half 2024 results: EPS: CN¥0.17 (up from CN¥0.13 in 1H 2023). Revenue: CN¥7.26b (flat on 1H 2023). Net income: CN¥307.6m (up 8.4% from 1H 2023). Profit margin: 4.2% (up from 3.9% in 1H 2023). Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 5.8% growth forecast for the Chemicals industry in Hong Kong. Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has fallen by 28% per year, which means it is performing significantly worse than earnings. Buy Or Sell Opportunity • Sep 26
Now 28% overvalued Over the last 90 days, the stock has fallen 18% to HK$6.95. The fair value is estimated to be HK$5.41, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 17%. Revenue is forecast to grow by 44% in 2 years. Earnings are forecast to grow by 208% in the next 2 years. Valuation Update With 7 Day Price Move • Sep 24
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to HK$6.37, the stock trades at a forward P/E ratio of 6x. Average forward P/E is 6x in the Chemicals industry in Hong Kong. Total loss to shareholders of 62% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at HK$5.40 per share. Reported Earnings • Aug 30
First half 2024 earnings released: EPS: CN¥0.17 (vs CN¥0.13 in 1H 2023) First half 2024 results: EPS: CN¥0.17 (up from CN¥0.13 in 1H 2023). Revenue: CN¥7.26b (flat on 1H 2023). Net income: CN¥307.6m (up 8.4% from 1H 2023). Profit margin: 4.2% (up from 3.9% in 1H 2023). Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Chemicals industry in Hong Kong. Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has fallen by 40% per year, which means it is performing significantly worse than earnings. Announcement • Aug 02
Dongyue Group Limited to Report First Half, 2024 Results on Aug 28, 2024 Dongyue Group Limited announced that they will report first half, 2024 results on Aug 28, 2024 Announcement • Jun 08
Dongyue Group Limited Approves Final Dividend for the Year Ended 31 December 2023 Dongyue Group Limited at its annual general meeting held on June 6, 2024, approved a final dividend of HKD 0.10 per Share for the year ended 31 December 2023. Upcoming Dividend • Jun 04
Upcoming dividend of HK$0.10 per share Eligible shareholders must have bought the stock before 11 June 2024. Payment date: 12 July 2024. Payout ratio is a comfortable 28% but the company is not cash flow positive. Trailing yield: 1.1%. Lower than top quartile of Hong Kong dividend payers (7.7%). Lower than average of industry peers (4.8%). Price Target Changed • May 21
Price target increased by 26% to HK$12.57 Up from HK$9.99, the current price target is an average from 4 analysts. New target price is 32% above last closing price of HK$9.51. Stock is up 25% over the past year. The company is forecast to post earnings per share of CN¥0.80 for next year compared to CN¥0.32 last year. Valuation Update With 7 Day Price Move • May 09
Investor sentiment improves as stock rises 23% After last week's 23% share price gain to HK$8.73, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 6x in the Chemicals industry in Hong Kong. Total returns to shareholders of 63% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at HK$4.99 per share. Reported Earnings • May 02
Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Full year 2023 results: EPS: CN¥0.32 (down from CN¥1.73 in FY 2022). Revenue: CN¥14.5b (down 28% from FY 2022). Net income: CN¥707.8m (down 82% from FY 2022). Profit margin: 4.9% (down from 19% in FY 2022). The decrease in margin was driven by lower revenue. Revenue missed analyst estimates by 1.3%. Earnings per share (EPS) exceeded analyst estimates by 2.8%. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 9.2% growth forecast for the Chemicals industry in Hong Kong. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth. Declared Dividend • Mar 29
Dividend of HK$0.10 announced Shareholders will receive a dividend of HK$0.10. Ex-date: 11th June 2024 Payment date: 12th July 2024 Dividend yield will be 1.4%, which is lower than the industry average of 8.1%. Payout Ratios Payout ratio: 28%. Cash payout ratio: 60%. Announcement • Mar 27
Dongyue Group Limited, Annual General Meeting, Jun 06, 2024 Dongyue Group Limited, Annual General Meeting, Jun 06, 2024. Reported Earnings • Mar 27
Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Full year 2023 results: EPS: CN¥0.32 (down from CN¥1.73 in FY 2022). Revenue: CN¥14.5b (down 28% from FY 2022). Net income: CN¥707.8m (down 82% from FY 2022). Profit margin: 4.9% (down from 19% in FY 2022). The decrease in margin was driven by lower revenue. Revenue missed analyst estimates by 1.3%. Earnings per share (EPS) exceeded analyst estimates by 2.8%. Revenue is forecast to grow 15% p.a. on average during the next 2 years, compared to a 7.3% growth forecast for the Chemicals industry in Hong Kong. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth. Price Target Changed • Mar 05
Price target increased by 11% to HK$9.22 Up from HK$8.33, the current price target is an average from 3 analysts. New target price is 37% above last closing price of HK$6.75. Stock is down 28% over the past year. The company is forecast to post earnings per share of CN¥0.31 for next year compared to CN¥1.73 last year. Announcement • Mar 02
Dongyue Group Limited to Report Fiscal Year 2023 Results on Mar 26, 2024 Dongyue Group Limited announced that they will report fiscal year 2023 results on Mar 26, 2024 New Risk • Feb 29
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 3.9% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 3.9% per year for the foreseeable future. Minor Risks Dividend is not well covered by cash flows (448% cash payout ratio). Large one-off items impacting financial results. Valuation Update With 7 Day Price Move • Feb 20
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to HK$6.56, the stock trades at a forward P/E ratio of 12x. Average forward P/E is 5x in the Chemicals industry in Hong Kong. Total returns to shareholders of 28% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at HK$5.09 per share. Buy Or Sell Opportunity • Feb 20
Now 29% overvalued after recent price rise Over the last 90 days, the stock has risen 18% to HK$6.56. The fair value is estimated to be HK$5.09, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 23% over the last 3 years. Earnings per share has grown by 46%. Revenue is forecast to decline by 3.4% in a year. Earnings are forecast to decline by 43% in the next year. Buy Or Sell Opportunity • Jan 25
Now 21% overvalued Over the last 90 days, the stock has fallen 4.8% to HK$5.75. The fair value is estimated to be HK$4.76, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 23% over the last 3 years. Earnings per share has grown by 46%. Revenue is forecast to decline by 3.4% in a year. Earnings are forecast to decline by 43% in the next year. Price Target Changed • Dec 21
Price target decreased by 13% to HK$8.33 Down from HK$9.54, the current price target is an average from 2 analysts. New target price is 54% above last closing price of HK$5.40. Stock is down 37% over the past year. The company is forecast to post earnings per share of CN¥0.38 for next year compared to CN¥1.73 last year. Major Estimate Revision • Dec 16
Consensus EPS estimates fall by 24% The consensus outlook for fiscal year 2023 has been updated. 2023 EPS estimate fell from CN¥1.02 to CN¥0.777 per share. Revenue forecast steady at CN¥17.1b. Net income forecast to grow 5.0% next year vs 5.0% growth forecast for Chemicals industry in Hong Kong. Consensus price target broadly unchanged at HK$9.55. Share price was steady at HK$5.43 over the past week. Major Estimate Revision • Dec 08
Consensus EPS estimates increase by 28% The consensus outlook for fiscal year 2023 has been updated. 2023 EPS estimate increased from CN¥0.797 to CN¥1.02. Revenue forecast steady at CN¥17.1b. Net income forecast to grow 5.0% next year vs 5.0% growth forecast for Chemicals industry in Hong Kong. Consensus price target down from HK$9.84 to HK$9.54. Share price fell 7.0% to HK$5.48 over the past week. Valuation Update With 7 Day Price Move • Oct 30
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to HK$6.39, the stock trades at a forward P/E ratio of 7x. Average forward P/E is 5x in the Chemicals industry in Hong Kong. Total returns to shareholders of 141% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at HK$4.13 per share. Price Target Changed • Oct 19
Price target decreased by 11% to HK$9.84 Down from HK$11.11, the current price target is an average from 3 analysts. New target price is 89% above last closing price of HK$5.21. Stock is down 35% over the past year. The company is forecast to post earnings per share of CN¥0.98 for next year compared to CN¥1.73 last year. Reported Earnings • Sep 16
First half 2023 earnings released: EPS: CN¥0.13 (vs CN¥0.76 in 1H 2022) First half 2023 results: EPS: CN¥0.13 (down from CN¥0.76 in 1H 2022). Revenue: CN¥7.20b (down 29% from 1H 2022). Net income: CN¥283.9m (down 83% from 1H 2022). Profit margin: 3.9% (down from 17% in 1H 2022). Revenue is forecast to grow 8.6% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Chemicals industry in Hong Kong. Over the last 3 years on average, earnings per share has increased by 46% per year but the company’s share price has only increased by 25% per year, which means it is significantly lagging earnings growth. Major Estimate Revision • Aug 31
Consensus EPS estimates fall by 20% The consensus outlook for earnings per share (EPS) in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from CN¥20.3b to CN¥18.4b. EPS estimate also fell from CN¥1.27 per share to CN¥1.02 per share. Net income forecast to shrink 38% next year vs 4.8% decline forecast for Chemicals industry in Hong Kong. Consensus price target down from HK$11.12 to HK$10.01. Share price fell 2.0% to HK$6.74 over the past week. Price Target Changed • Aug 30
Price target decreased by 10.0% to HK$10.01 Down from HK$11.12, the current price target is an average from 5 analysts. New target price is 47% above last closing price of HK$6.81. Stock is down 23% over the past year. The company is forecast to post earnings per share of CN¥1.35 for next year compared to CN¥1.73 last year. Announcement • Aug 08
Dongyue Group Limited to Report First Half, 2023 Results on Aug 25, 2023 Dongyue Group Limited announced that they will report first half, 2023 results on Aug 25, 2023 Valuation Update With 7 Day Price Move • Jul 13
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to HK$7.30, the stock trades at a forward P/E ratio of 5x. Average forward P/E is 5x in the Chemicals industry in Hong Kong. Total returns to shareholders of 136% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at HK$12.70 per share. Announcement • Jun 15
Dongyue Group Limited Provides Earnings Guidance for the Six Months Ending 30 June, 2023 Dongyue Group Limited provided earnings guidance for the six months ending 30 June, 2023. For the period, the Board expected that the Group may record a significant decrease in its net profit attributable to owners of the Company, as compared with that for the six months ended 30 June 2022. Valuation Update With 7 Day Price Move • Jun 15
Investor sentiment deteriorates as stock falls 20% After last week's 20% share price decline to HK$5.67, the stock trades at a forward P/E ratio of 4x. Average forward P/E is 5x in the Chemicals industry in Hong Kong. Total returns to shareholders of 96% over the past three years. Upcoming Dividend • Jun 07
Upcoming dividend of HK$0.60 per share at 8.2% yield Eligible shareholders must have bought the stock before 14 June 2023. Payment date: 13 July 2023. Payout ratio is a comfortable 31% and this is well supported by cash flows. Trailing yield: 8.2%. Within top quartile of Hong Kong dividend payers (7.7%). In line with average of industry peers (7.6%). Price Target Changed • Apr 11
Price target decreased by 7.0% to HK$11.05 Down from HK$11.88, the current price target is an average from 5 analysts. New target price is 34% above last closing price of HK$8.27. Stock is down 9.1% over the past year. The company is forecast to post earnings per share of CN¥1.13 for next year compared to CN¥1.73 last year. Reported Earnings • Mar 29
Full year 2022 earnings: EPS and revenues exceed analyst expectations Full year 2022 results: EPS: CN¥1.73 (up from CN¥0.98 in FY 2021). Revenue: CN¥20.0b (up 26% from FY 2021). Net income: CN¥3.86b (up 86% from FY 2021). Profit margin: 19% (up from 13% in FY 2021). Revenue exceeded analyst estimates by 10%. Earnings per share (EPS) also surpassed analyst estimates by 20%. Revenue is forecast to grow 2.2% p.a. on average during the next 3 years, compared to a 4.6% growth forecast for the Chemicals industry in Hong Kong. Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has only increased by 41% per year, which means it is significantly lagging earnings growth.